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Influence of dialysate calcium concentration and vitamin D on
serum parathyroid hormone during repetitive dialysis. An acqte
rise or decrease in parathyroid hormone (PTH) secretion was
found in 30 patients, dialyzed with, respectively, low (5 mg/
100 ml) or high (7.5 rng/l00 ml) calcium concentration. The per-
centage changes were, respectively, + 35% and — 47% when a
N-terminal antiserum measuring predominantly the glandular
PTH was used. Only relatively small changes, respectively, + 3%
and —17%, were found using a C-terminal antiserum which
detects preferentially smaller PTH fragments. Predialysis serum
PTH concentration increases significantly with increasing dura-
tion of repetitive hemodialysis treatment using an intermediate
(6 and 6.4 mg/lOO ml) concentration of calcium in the dialysate.
No such increase could be found in two other groups of patients
treated with high-calcium (7.5 mg/i® ml) dialysis. Moreover, a
significant but temporary decrease in predialysis serum PTLI
concentration occurred two months after a rise in dialysate cal-
cium concentration from 6 to 7.5 mg/i® ml. Treatment with
pharmacologic doses of vitamin D3 in selected patients (renal
osteodystrophy or children) always resulted in a definite sup-
pression of serum PTH concentration during 14 treatment
periods in ten patients. After cessation of vitamin D3 treatment,
serum PTH concentration returned to high levels in four out of
five patients. These data fail to confirm the long-term involution
of secondary hyperparathyroidism using high-calcium dialysis.
Vitamin D treatment, however, results in a much more pro-
nounced decrease in serum PTH concentrations, but sustained
therapy is necessary.
Influence de Ia concentration du calcium dans le ham de dialyse
et de Ia vitamine D sur Ia concentration sérique d'hormone pan-
thyroidienne au cours de l'hémodialyse iterative. Une augmenta-
tion ou une diminution aiguës de Ia sécrCtion d'hormone para-
thyroidienne (PTH) a été observée chez 30 malades dialyses, res-
pectivement, avec des concentrations de calcium faible (5 mg-
i® ml) ou élevee (7,5 mg/i® ml). Les pourcentages de modi-
fication ont été respectivement de + 35% et — 47% quand un
antiserum N terminal, qui mesure surtout Ia PTH glandulaire, a
été utilisé. Des modifications minimes, respectivement, 3% et
— 17%, ont été mises en evidence par un antiserum C terminal
qui détecte preferentiellement des fragments plus petits de Ia
PTH. La PTH sérique avant la dialyse augmente significative-
ment en fonction de Ia durée du traitement par l'hémodialyse
quand une concentration de calcium mntermédiaire (6 et 6,4 mg/
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100 ml) est utilisee. Cette augmentation n'est pas constatée chez
les malades de deux autres groupes traités avec des concentra-
lions de calcium elevees (7,5 mg/i® ml). De surcroit, une dimi-
nution significative mais éphémère de Ia concentration sérique
pre-dialytique de PTH est survcnue deux mois aprés l'augmenta-
tion de Ia concentration du calcium du bain de 6 a 7,5 mg/i® ml.
Le traitement par des doses pharmacologiques de vitamine D3
chez des malades sélectionnés (osteodystrophie rénale, enfants)
a toujours pour consequence une suppression nette de l'aug-
mentation de Ia PTH sérique, cela au cours de 14 traitements
chez dix malades. Aprés l'arrCt de Ia vitamine D3 chez cinq
malades Ia PTH sérique est revenue a des valeurs elevees chez
quatre d'entre eux. Ces résultats ne confirment pas Ia reduction
a long terme de l'hyperparathyroldisme secondaire par l'utilisa-
tion d'un bain de dialyse riche en calcium. Le traitement par Ia
vitamine D, cependant, a pour consequence une diminution
beaucoup plus importante de Ia PTH sCrique mais un traitement
ininterrompu est nécessaire.
Renal insufficiency, either acute or chronic, is
associated with secondary hyperparathyroidism. This
has been confirmed by morphological findings in the
parathyroid glands [1], by the presence of specific bone
lesions [2] and also by direct measurement of serum
or plasma parathyroid hormone concentration [3-5].
These parathyroid hormone (PTH) measurements,
however, must be interpreted carefully because of the
altered distribution of different PTH components in
the presence of renal insufficiency. Indeed, the intact
glandular hormone (mol wt 9,500) retains its normal
short half-life (±20 mm), but the main breakdown
product, the biologically inactive "peripheral" para-
thyroid hormone (mol wt 6000 to 7000) accumulates
in serum since its half-life increased markedly (>24 hr,
[6]).
The pathogenetic mechanisms responsible for this
secondary hyperparathyroidism are essentially known:
phosphate retention [7], abnormal metabolism of vita-
min D [8, 9] and skeletal resistance to the action of
parathyroid hormone [10]. The exact interrelationship
and the sequential importance of these factors, how-
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ever, are still disputed [11]. All factors mentioned,
however, tend to decrease ionized serum calcium con-
centration, which is known to be the best stimulus for
parathyroid hormone secretion.
Since secondary hyperparathyroidism, although
adaptive in origin, can have deleterious effects on bone,
especially in the case ofprolonged survival due to success-
ful repetitive hemodialysis, different kinds of therapy
and prevention have been proposed: diminution of the
phosphorus intake or of its gastrointestinal absorption
[12], calcium supplementation orally [13], higher cal-
cium concentration in the dialysate [14] and admini-
stration of vitamin D or its analogues [15].
For better understanding of these therapeutic possi-
bilities, we have studied the short- and long-term in-
fluence of dialysate calcium concentration and vitamin
D3 treatment on parathyroid hormone secretion in
patients receiving repetitive long-term hemodialysis
(Table 1).
Methods
Patients. Patients with end-stage renal insufficiency
necessitating chronic hemodialysis were studied. They
all received aluminum hydroxide orally in a nearly
constant dose (2.5 to 6 g/day) during the observation
period.
In group A serum for measurements of calcium,
phosphorus and alkaline phosphatase was taken before
and at the end of their usual eight-hour dialysis. Para-
thyroid hormone was also measured using two different
antibovine parathyroid antisera (BW 211/32 and A-VI-
2, see below). In a first experiment (4/15/1973) the
usual dialysate calcium concentration of 7.5 mg/lOOml
was used but in the second (5/15/1973) the dialysate
calcium was only 5 mg/100 ml.
In group B the dialysate calcium concentration was
6 mg/100 ml until 11/2/1972 and 7.5 mg/100 ml after-
wards. All other dialysate constituents remained un-
changed (sodium, 137 mEq/liter; potassium, 1.0 mEq/
liter; acetate, 35 mEq/liter; magnesium, 1.0 mEq/
liter). Dialysis was performed during eight hours
twice-weekly with a twin-coil kidney. Serum for
measurement of parathyroid hormone was obtained
before the start of the dialysis three times before and
eight times after the rise in dialysis calcium concentra-
tion. The total observation time ranged from 4 to
15 months after the rise in dialysate calcium. Predi-
alysis serum calcium and phosphorus concentrations
and alkaline phosphatase activity were measured
twice monthly and the mean value for each patient
during the month preceding the sampling for serum
PTH was calculated. Two patients died during the last
month of the observation: one from overhydration
and the other from a cerebrovascular accident. One
other patient was transferred to another dialysis center
for social reasons (in September, 1973).
Group C was started on regular hemodialysis only
Table 1. Diagram of the different study protocols and their aims in the study of parathyroid hormone secretion
Group Patients Age of Duration (months) Dialysate Selection of Anti-PTH Aims of the study: Influence
N(M/F) patients
(range)
yr
of previous hemo-
dialysis twice
weekly, 8 hr
(range)
calcium patients antiserum on PTH secretion
A 30 38 73 7.5 No N-terminal Acute study: Effects of different
(21/9) (16—67) (1—321) 5 and
C-terminal
dialysate calcium concentra-
tions
B 10 31 23 6 Exclusion of N-terminal Chronic study: a) idem as for
(6/4) (20—44) (2—75) 7.5 patients with
criteria for
group E
group; b) prospective study of
a rise in dialysate calcium con-
centration from 6 to 7.5 mgI
100 ml
C 8 46 2 7.5 Exclusion of N-terminal Chronic study: prospective study
(5/3) (22—67) (0.5—4.5) patients with
criteria for
group E
of the influence of a dialysate
calcium concentration of
7.5 mg/100 ml
D 26 38 9 6.4 No N-terminal Chronic study: cross-sectional
(14/12) (6-54) (1—44) study of the influence of dura-
tion of chronic hemodialysis
E 10 28 13 7.5 Severe radiological N-terminal Chronicstudy: prospectivestudy
(5/5) (13-49) (0—42) signs of renal
osteodystrophy
or young age
(<18)
of the influence of vitamin D
therapy
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after 11/2/1972, each time using a dialysate calcium
concentration of 7.5 mg/100 ml. Predialysis serum
PTH measurements were performed six to eight times
in each of these patients during a mean total period of
nine months (range: seven to ten months).
Group D was treated with regular hemodialysis at
another hospital (University Hospital, Ghent, Service:
Prof. R. Ringoir) with a dialysate calcium concentra-
tion of 6.4 mg/lOO ml. Serum for PTH measurement
was taken only once before the start of dialysis.
Group E was treated with pharmacologic doses of
vitamin D3 because of typical signs of osteitis fibrosa
or because of their young age. The clinical history of
some of these patients has been discussed previously
[16]. Serum for parathyroid hormoqe measurement
was taken at regular intervals before, during and after
the end of vitamin D treatment (which was discon-
tinued when the serum calcium concentration in-
creased to > 11 mg/100 ml or radiographic signs of
renal osteodystrophy had disappeared). Further treat-
ment consisted of regular hemodialysis as for group A
patients and oral administration of aluminum hy-
droxide in constant dosage.
Methods. Serum calcium and phosphorus concentra-
tions and alkaline phosphatase activity were measured
with the aid of an autoanalyzer. Normal adult values
for serum calcium range from 8.9 to 10.6 mg/lOO ml,
2.5 to 4.25 mg/100 ml for serum phosphorus and 40 to
140 lU/mI for serum alkaline phosphatase. Serum
parathroid hormone was measured with a radioim-
munoassay method, previously described in detail [17,
18]. The final serum concentration was 10 to 20% in a
total incubation volume of 0.5 ml. Phase separation
was performed with dextran-coated charcoal (20 mg of
charcoal, Norit A; 3mg of Dextran 70) after non-equili-
brium incubation for seven days at 4°C. Purified bovine
PTH (gift of Dr. G. Aurbach) was used as an internal
standard since previous experiments indicated a
parallel inhibition with serum of hyperparathyroid
patients diluted serially with serum of hypoparathyroid
patients. Antiserum BW 211/32, which mainly reacts
with the glandular form of the hormone and also cross-
reacts with the synthetic 1—34 bPTH fragment, was
used in all studies. For the experiments on patients of
group A and for the gel filtration studies another anti-
serum, A-Vl-2, was also used. This antiserum does not
cross-react with the biologically active N-terminal
fragment and recognizes mainly a parathyroid hor-
mone fragment with a mol wt of about 7,000. Normal
values for serum parathyroid hormone are 210 pg of
bovine PTH/ml for antiserum BW 211/32 and <400 pg
of bPTH/ml for A-VI-2. The between-assay variation
coefficient was 10.8% for a sample with 1513 pg/mI
and 7.7% for a sample with 282 pg/mi, both measured
with antiserum BW 211/32. For antiserum A-Vl-2 this
variation coefficient was 7.8% for a sample with 1954
pg/mi and 8.7% for a sample with 1193 pg/ml.
Gel filtration on Bio Gel P-b (Bio-Rad) was per-
formed on columns of 16 x 700 mm at 4°C using a
slightly acidic buffer (NaC1, 0.14 bovine serum
albumin, 0.25%; pH 3 with HC1). Fractions of 2 ml
were collected at a flow rate of 12 ml/hour using a
peristaltic pump and an automatic fraction collector.
The eiution position of glandular human parathyroid
hormone and '25iodide was identified by a previous
run on the same column in identical circumstances.
One-tenth of each fraction (0.2 ml) was assayed for
parathyroid hormone immunoreactivity with both
antisera (BW 211/32 and A-VI-2). The results were
expressed as percent inhibition of the binding of tracer
bPTH to its antiserum in the absence, of added cold
hormone. This expression was chosen because it is
probable that not all fractions diluted out linearly to
the glandular bPTH standard.
Results
A. Short-term effects of dialysate calcium on serum
parathyroid hormone levels, a. Dialysate calcium
concentration of 7.5 mg/100 ml. Mean serum calcium
concentration in 30 patients attending the dialysis
center (group A) increased from a predialysis value of
9.38±0.19 (mean±sEM) to 11.19±0.2 mg/100 ml at
the end of hemodialysis (Pc 0.001). Serum phos-
phorus. concentration decreased and serum alkaline
phosphatase activity increased significantly (Fig. 1).
The calcium x phosphorus product decreased from
43.3 to 37.8 (P.c 0.05).
Serum parathyroid hormone, measured with anti-
serum BW 21 1/32, decreased from 666± 165 to 350±
101 pg bPTH/ml (Pc 0.01). This is a mean percentage
decrease of 47.5%. When, in the same samples, para-
thyroid hormone was assayed with antiserum A-VI-2, a
decrease from 3019 407 to 2495 415 pg of bPTH/ml
occurred (P<0.OOi). This is a percentage decrease of
only 17.4% (Fig. 1).
b. Dialysate calcium of 5 mg/100 ml. When the
30 patients of group A were dialyzed with a dialysate
calcium of only 5 mg/100 ml, the mean predialysis
serum calcium concentration (9.36 0.13 mg/100 ml)
decreased to 8.93 0.12 at the end of the dialysis
(PcO.00i). Mean serum phosphorus concentration
also decreased and serum alkaline phosphatase
activity again increased significantly (Fig. 1). The cal-
cium x phosphorus product decreased from 42.7 2.5
to 31.5± 1.4 (Pc 0.001). Serum parathyroid hormone
measured with antiserum 13W 211/32 increased from a
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Fig. 1. Mean (± SEM) pre- and
postdialysis serum concentra-
tions of calcium, phosphorus,
alkaline phosphatase and para-
thyroid hormone, measured
with two different antisera, in
30 patients (group A) during a
single dialysis with low (5 mgI
100 ml) or high (7.5 mg/100 ml)
calcium concentration.
predialysis value of 606 119 to 820 152 pg of bPTH/
ml (P <0.001) at the end of dialysis; measured with
antiserum A-VI-2 a small increase from 3186 242 to
3294 235 pg of bPTH/ml occurred (P <0.05). End-
dialysis values were thus respectively 135.3% and
l03.4% of the predialysis value for the two antisera
used (Fig. 1).
c. Gel filtration of serum before and after dialysis.
Two serum samples (2 ml) from the same patient, one
taken before and one at the end of hemodialysis with
a dialysate calcium concentration of 7.5 mg/100 ml
were analyzed by gel filtration on a Bio-Gel P-10
column. Predialysis serum parathyroid hormone eluted
mainly in the same position as a glandular bovine and
human PTH extract when antiserum BW 211/32 was
used, while antiserum A-VI-2 detected much more im-
munoreactivity in the lower molecular regions. After
dialysis a marked decrease in immunoreactivity as
measured with BW 211/32 occurred (from 2420 to
880 pg of bPTH/ml), corresponding to the diminished
area of the "glandular" PTH fraction measured with
this antiserum in the gel filtration fractions (Fig. 2).
-5-S
Ca, mg/100 mlU—
1**1I
8 hr
However, a much smaller decrease in parathyroid
hormone immunoreactivity was found when antiserum
A-VI-2 was used as well in the same whole serum (a
decrease from 6390 to 4960) as in the same gel filtra-
tion fractions (Fig. 2).
B. Long-term influence of dialysate calcium on para-
thyroid hormone secretion, a. The influence of the dura-
tion of previous therapy with regular hemodialysis
using a dialysate calcium of 6 mg/100 ml can be
appreciated by a positive correlation coefficient (r =
0.76, N= 10, P<0.02) between duration of previous
therapy (90 30 weeks, mean SEM) and predialysis
serum parathyroid hormone (1069 258 pg of bPTH/
ml) in the ten patients of group B (Fig. 3).
In another group of 26 patients (group D) treated at
another hospital (University Hospital, Ghent) with a
dialysate calcium of 6.4 mg/100 ml, a similar positive
correlation coefficient (r =0.50, N= 26, P <0.01) could
be found between the duration of previous hemodialysis
therapy (35±8 wks) and predialysis serum parathyroid
hormone levels (480±94 pg of bPTH/ml) (Fig. 3).
b. Long-term influence of a rise in dialysate calcium
Before
Dialysate calcium
7.5 mg/100 ml
After Before After
Dialysate calcium
5 mg/l00 ml
bPTH, pg/mi
As BW As A VI-2
211/32
1*-.) (o--o)
750 3000
500 2000
250 1000
* P<0.05
** P<0.01
P<0.00l
0 8hr
12
ii
10
P, mg/l00 ml
o- —o
5
4
3
2
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Bio-Gel PlO gelfiltration
Column: 16 x 700mm
Sample: 2 ml of serum
Elution buffer: NaCI, 0.14 M,
BSA, 0.25%; pH 3
Elution time: 2 mi/lO mm
4°C
Fig. 2. Gel filtration on Bio Gel
P-Jo of 2 ml of serum taken be-
fore (E) or after the end ()
of hemodialysis with high (7.5
mg/100 ml) calcium concentra-
tion in patient 16. Each frac-
tion (2 ml) was assayed with
two different antiparathyroid
hormone antisera: BW 211/32
( ) and A-VI-2 ( ).
bPTH 1-125
—— Antiserum BW 211/32
— AntiserumA-VI-2
o Before
high calcium dialysis
• After
0
10
20
30
40
50
60
70
80
90
100
a
0
a0a
a
Elution volume, ml
concentration (patients of group B). Mean predialysis
serum calcium concentration measured during three
periods of one month in the ten patients of group B
were, respectively, 9.26 0.16 (mean SEM), 8.97 0.17
and 9.26 0.16, when the dialysate calcium concentra-
tion was only 6 mg/100 ml. After the rise in dialysate
calcium concentration to 7.5 mg/100 ml, the predialysis
serum calcium concentration increased in all patients
to a mean of 10.17 0.22 in January, 1973 and 10.20
0.18 in February, 1973 (paired t test compared to
October, 1972: P<0.01). During further follow-up,
however, predialysis serum calcium levels decreased
again (Fig. 4).
Predialysis serum phosphorus concentration de-
creased from 4.10 0.33 and 4.84 0.44 during the low
dialysate calcium period to 3.45 0.21 and 3.40 0.27
L1L I I I I I
1) 50 60 70 80 90 100 110 120
in the January and February period, respectively,
(P <0.025).
Mean predialysis serum alkaline phosphatase was
higher than normal during the low dialysate calcium
period (241 49 to 261 55 IU/ml). A significant de-
crease was not found until five months after the rise in
dialysate calcium concentration.
Predialysis serum parathyroid hormone levels,
measured three times during the low dialysate calcium
period did not change significantly. However, two
months after the rise in dialysate calcium concentra-
tion to 7.5 mg/l00 ml, a decrease in predialysis serum
PTH levels was found (645 173 pg of bPTH/ml). This
value was significantly different from the previous
October, 1972 value of 1069±258 when calculated
with a paired t test (P<0.05). Because some doubt
Fig. 3. Correlation between
total duration of previous treat-
ment with repetitive hemodialy-
sis, using an intermediate (6 to
6.4 mg/100 ml) dialysate cal-
cium concentration, and pre-
dialysis serum parathyroid hor-
mone concentration (antiserum,
BW 211/32).
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t
6 mgJlOO ml Dialysate calcium concentration .' 7.5 mg/tOO ml/////////,Z'/I//5////I////////#,
0
0
o Group A (N = 10)r = 0.76 P < 0.02
• Group D (N = 26) r = 0.50 P < 0.01
Group A + D (N 36) r = 0.701 P < 0.001
Duration of repetitive hemodialysis, weeks
bPTFI,pg/mi 2:
Aic P'S', lU/mi
II III IV V VI VII VIII Ix
0-—u Ca, mg/ISO ml
s-U—. P,mg//OOml 12.5
1250
1000
750
500
C =P<0.05
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C C = F < 0.01
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7.5
5
Fig. 4. Mean (± SEM) predialy-
sis serum concentration of cal-
cium, phosphorus, alkaline
phosphatase and parathyroid
hormone (antiserum, BW 211/
32) in ten patients (group B)
dialyzed with intermediate (6
mg/100 ml) and high (7.5 mgI
100 ml) calcium concentration.
250 2.5T +-
June July Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jane July Aug Sept
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about the normal distribution of these values could
exist the same data were analyzed statistically using a
Wilcoxon rank sum test for paired data (2a=0.05) and
a paired Student's t test after logarithmic transforma-
tion (P <0.02). During the subsequent months, how-
ever, serum PTH levels increased again progressively
and were no longer different from the levels obtained
during the period of low calcium dialysate (Fig. 4).
c. Influence of prolonged treatment with high calcium
dialysate on serum parathyroid hormone (group C
patients). Mean predialysis serum parathyroid hor-
mone levels obtained in the first and second month of
observation were, respectively, 335 69 and 404 61 pg
of bPTH/ml in the eight patients of group C. After treat-
ment with long-term repetitive hemodialysis using a
high calcium dialysate (7.5 mg/100 ml) during a mean
period of seven and nine months, the predialysis serum
parathyroid hormone concentration had not changed
significantly (Table 2).
C. Influence of pharmacologic doses of vitamin D3
on parathyroid function (group E). The high predialysis
serum parathyroid hormone levels before (1410 224
Table 2. Individual results of predialysis serum parathyroid hormone (PTH) measurements (N-terminal antiserum, BW 211/32)
in eight patients (group C) who always have been treated with high-calcium (7.5 mg/100 ml) dialysis
Patient
No.
Sex Age Observation period Duration of
yr follow-up
I II III IV I-IV
months
1 M 61 100 300 170 340 10
2 M 34 460 620 450 560 10
3 M 53 650 490 380 680 10
4 F 22 260 540 320 190 10
5 M 40 360 380 190 250 10
6 F 54 440 380 380 440 9
7 F 37 360 460 740 440 7
8 M 67 50 60 480 230 7
Mean PTH, pg/in! 335 404 389 391
SEM 69 61 64 61
Pairedttest NS NS NS
Table 3. Age, sex, duration of previous hemodialysis and duration and dosage of vitamin
Patient Age Sex Duration Duration Dosage of Before During
No. yr of pre-
vious dial-
yses
weeks
of treat- D3/month
ment nig
weeks PTH Ca AP PTH Ca AP
pg bPTH/ml mg/IOU ml lU/mI pg bPTH/ml mg/IOU in! lU/mi
9b 49 F 6 30 120 2500 9.32 787 1520 9.56 646
10 16 M 13 26 60 2360 9.90 355 612 10.00 300
11 17 M 62 26 60 535 10.68 90 515 11.18 106
12 15 F 2 24 30 1100 9.50 199 440 10.10 141
13 13 M 15 20 60 2120 8.83 280 — — —
14b 30 M 55 16 180 481 9.47 742 — — —
44 F 24 2 120 805 10.75 115 — — —
16b I 30 F 11 28 120 650 9.67 612 780 9.16 174
II (30) (F) 76 13 60 350 8.60 101 50 11.60 82
17b 1 42 F 1 6 120 2520 8.80 935 — — —
II (42) (F) 14 21 60 480 11.70 1027 295 11.12 648
18' I 26 M 130 13 120 2380 8.83 831 920 9.97 450
II (26) (M) 148 6 120 940 10.30 217 — — —
III (26) (M) 168 26 15 2500 9.90 108 870 9.44 147
Mean 28.2 51.8 18.35 89 1410 9.73 485 667 10.24 299
SEM or 13-49 5M/5F 2—168 2—30 15—180 244 0.24 96 142 0.29 121
range (14) (9)
Paired ttest
Compared with values "before"
t — — — 3.16 2.49
P <0.02 NS <0.05
a With individual and mean (± SEM) values of serum calcium, alkaline phosphatase (AP) and parathyroid hormone.
bPatients with severe radiological signs of renal asteodystrophy.
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pg bPTH/ml) the start of the vitamin D3 treatment de-
creased significantly during (667 142) and at the end
(267 35) of the treatment period (Table 3). Serum
calcium was significantly increased in all patients at
the end of therapy with mean values slightly above
normal (11.23 0.22 mg/l00 ml). Serum alkaline
phosphatase decreased dramatically to nearly normal
values at the end and after arrest of treatment. Serum
phosphorus did not change significantly during the
whole treatnient period. In four out of five patients
serum PTH increased again when the serum calcium
concentration returned to normal values more than
one month after the arrest of vitamin D treatment.
Discussion
Influence of short-term changes in serum calcium on
parathyroid hormone secretion. The difference in cal-
cium concentration between the dialysate fluid and the
plasma ultrafiltrate is the most important factor re-
gulating the external calcium balance during hemo-
dialysis [19, 20]. In previous studies [21, 22] we found
a decrease in the ionized serum calcium concentration
during hemodialysis with a dialysate calcium con-
centration of 5 mg/lOO ml, and an increase when a
dialysate calcium of >6 mg/100 ml was used. Only the
total serum calcium concentration was measured in
the present study, but the same significant change in
D3 treatment in ten patients (group E)
At the end One month or more after
cessation of treatment
pg
PTH
bPTH/
ml
Ca
mg/100 ml
AP
lU/mi
PTH Ca AP
pg bPTH/mi ,ng/lO0 ml lU/mi
460
280
250
290
315
370
420
356
60
400
180
210
50
100
267
35
14
4.76
<0.001
10.48
12.80
10.63
10.30
11.59
12.10
12.16
11.30
11.96
11.27
10.76
10.62
11.20
10.06
11.23
0.22
4.47
<0.001
470
189
115
99
156
331
113
162
93
1200
225
209
109
113
261
83
2.78
<0.02
— — —
240 10.90 110
— — —
— — —
— — —
— — —
— — —
1685 10.41 195
350 8.80 82
— —
— — —
940 10.30 217
1380 10.00 105
— — —
919 10.08 142
281 0.35 133
5
— — —
NS NS NS
postdialysis serum calcium concentration was found
with dialysate calcium concentrations of 5 and 7.5 mg/
100 ml, respectively. Serum PTH increased during
low-calcium dialysis and decreased during high-
calcium dialysis. The (percentage) variations, however,
are much more important when PTH is measured with
an N-terminal antiserum as compared to those
measured with a C-terminal antiserum. This difference
in results can be explained by the antigenic characteris-
tics of the two antisera. Because of the short half-life
of the intact glandular hormone, even in case of renal
insufficiency [23, 24] the values obtained with the N-
terminal antiserum reflect the acute response of the
parathyroid glands to changes in serum calcium con-
centration. The decrease of new glandular hormone
secretion, however, does not have an immediate effect
on the serum concentration of the inactive fragments
(measured by antiserum A-VI-2) because of their long
half-life in circulation [25]. Possible interference by
elimination of small parathyroid hormone fragments
through the dialysis membrane can be excluded by the
absence of significant amounts of immunoreactivity in
the plasma ultrafiltrate, obtained with the membrane
used during hemodialysis.
The problem of the autonomy of the parathyroid
glands in patients with renal insufficiency has been
studied previously during calcium infusion studies by
Reiss, Canterbury and Kantor [26], Massry et al [27]
and Genuth et al [28] who found parathyroid hormone
to decrease in most patients. O'Riordan et al [24], how-
ever, could not find such a decrease. Berson and
Yalow [29] and Goldsmith et al [23] found differences
in parathyroid hormone suppressibility according to
the antisera used. Antisera C-329 [29] and CH-l4-M
[23], measuring mainly the intact hormone, as our
antiserum BW 211/32 [18] detected acute decreases in
serum parathyroid hormone after important rises in
serum calcium concentration. Antiserum 273 [29] and
GP-l-M [23] like our antiserum A-VI-2 could only
detect minimal and slow decreases. Dialysis with ex-
tremely high (11.5 mg/l00 ml) or low (3.5 mg/100 ml)
calcium concentration could influence serum para-
thyroid hormone in the same manner in four patients
[30] as we found with less extreme variation in dialy-
sate calcium concentrations.
Although the hypersecretion of parathyroid hor-
mone can be suppressed by increasing the serum cal-
cium concentration, normal values were not attained
in our patients at the end of the high-calcium dialysis
despite a mean supranormal end-dialysis serum cal-
cium of 11.18 mg/100 ml. This resembles the situation
in many cases of "primary" hyperparathyroidism
where partial suppressibility seems to be more frequent
than real autonomy [181. A possible explanation could
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be the phenomenon that excess amounts of para-
thyroid tissue (as can be obtained by isologous para-
thyroid transplantation [31]) need a higher than usual
calcium concentration before total arrest of secretion
occurs.
Long-term influence of dialysate calcium on para-
thyroid hormone secretion. In two independent groups
of patients (group B and D) a positive correlation was
found between the duration of previous treatment
with repetitive hemodialysis and serum parathyroid
hormone. This positive correlation indicates that the
pathogenic mechanisms of secondary hyperpara-
thyroidism still operate during this kind of low-calcium
dialysis. A similar positive correlation was found pre-
viously by Johnson et al [32] who used a calcium
dialysate concentration of only 2.6 mEq/liter, but
Fournier et al [33] were unable to find such a correla-
tion. It is likely that other factors can also influence
PTH secretion although we could not find any other
significant correlation (age, serum creatinine, phos-
phorus or calcium) with the PTH level. This progres-
sion in secondary hyperparathyroidism is in agreement
with previous clinical [34, 35], radiological [27, 36] and
histological [37, 38] observations indicating that pro-
longed treatment with repetitive hemodialysis using
low or intermediate calcium concentration (<6.5 mg/
100 ml) in the dialysis fluid aggravates bone lesions.
A high dialysate calcium concentration has recently
been advocated for prevention or cure of secondary
[14, 39] and even "tertiary" [40] hyperparathyroidism.
Indeed, when dialysate calcium and predialysis serum
phosphorus concentrations were manipulated [33],
the lowest predialysis serum concentration of para-
thyroid hormone was found when the serum phos-
phorus concentration was lowered by oral administra-
tion of aluminum hydroxide together with the use of
what was called "high (>6 mg/100 ml) calcium dia-
lysis." However, during these experiments no de-
finitely high dialysate calcium was used, the observa-
tion periods were short and both dialysate calcium
and phosphorus absorption were changed together.
Previous measurements of serum parathyroid hormone
after short-term high-calcium dialysis indicated a good
suppression with 8 mg/I 00 ml [14, 39] but not with
7 mg/lOO ml [32].
Our data on the ten patients of group B indicate
that a rise in dialysate calcium from 6 to 7.5 mg/lOO ml
results in an increase in predialysis serum calcium and
a reciprocal decrease in serum parathyroid hormone
(period IV; Fig. 4). However, after several months of
continuous high-calcium dialysis, a progressive return
of serum calcium, serum phosphorus and serum PTH
to the previous concentrations occurred despite the
fact that all therapy remained the same. This does not
mean that a high dialysate calcium was absolutely in-
effective because it prevented the prior continuous rise
in serum PTH as the duration of repetitive dialysis in-
creased. The same stabilization in serum parathyroid
hormone levels was indeed found in a group of patients
(group B) who were always treated with high (7.5 mg/
100 ml) calcium dialysis (Table 2).
One other group has repeatedly argued that it ob-
serves a progressive decrease in serum PTH using
high-calcium dialysis [14, 39, 41]. Numerous differ-
ences, however, exist between the two study protocols:
their dialysis frequency was higher (three times vs.
two times a week), their blood sampling was performed
the day after dialysis (vs. our predialysis sampling) and
their anti-PTH antiserum was C-terminal (vs. our N-
terminal one), their patients were new ones and ours
were already treated with repetitive hemodialysis before
this study. The difference in sampling time is probably
not very important but this could be the case for the
antisera difference if the parathyroid glands can secrete
independently the intact and the inactive fragment. In-
sufficient data, however, are presently available on this
possibility [25]. Two major protocol differences, how-
ever, seem to be important: first a higher frequency of
dialysis (Mayo Clinic) could have resulted in a more
positive calcium balance. This total calcium transfer,
a kind of product of the dialysate calcium concentra-
tion and duration of dialysis, could be the determinant
factor in the PTH secretion. The second important
difference is one of patient selection: our patients were
already treated with an intermediate calcium dialysis
resulting in a nearly normalization of the serum cal-
cium and phosphorus concentrations, which was ap-
parently not the case for the Mayo Clinic patients,
who were newly dialyzed patients. Comparing the
PTH levels during a period of intermediate calcium
(6 mg/lOO ml) dialysis and subsequently during high-
calcium (7.5 mg/tOO ml) dialysis is probably a better
indication of the effect of the rise in dialysate calcium
concentration per se.
Influence of vitamin D treatment on parathyroid hor-
mone secretion. Although the presence of osteitis
fibrosa is usually associated with excessive parathyroid
hormone secretion and not with vitamin D deficiency,
improvement of this bone lesion during chronic renal
failure has been achieved by vitamin D treatment,
using either dihydrotachysterol [42] or vitamin D3
[43, 16]. The influence of this treatment on PTH secre-
tion, however, has not been studied previously. During
prolonged treatment with pharmacologic doses of
cholecalciferol, an important suppression of PTH
secretion was found in all our patients. With very few
exceptions, a simultaneous increase in serum calcium
and a decrease in serum parathyroid hormone and
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serum alkaline phosphatase occurred. At the end of
treatment, when slight hypercalcemia existed in eight
patients, inappropriately high parathyroid hormone
levels still existed in six patients. When the vitamin D
treatment was arrested, PTH levels increased rapidly
again in four out of five patients studied. These two
phenomena suggest that in most cases parathyroid
hyperfunction is only temporarily suppressed by a
higher than normal serum calcium concentration, and
that sustained treatment is thus unnecessary. From in-
dividual roentgenological and histological bone analy-
sis in our patients, we found [161 that partial healing of
the osteitis fibrosa could already occur before the de-
crease in serum PTH. This suggests that vitamin D
treatment together with high-calcium (7.5 mg/100 ml)
dialysis first restores a bone calcium deficit and results
afterwards in a progressive rise in serum calcium which
finally suppresses parathyroid hormone secretion.
Therapeutic considerations. The evolution of serum
parathyroid hormone concentrations in patients with
renal insufficiency can be important since secondary
hyperparathyroidism in this disease can be considered
to be an index for the primary disturbance of calcium
metabolism [7]. From our long-term studies we can con-
clude that secondary hyperparathyroidism, once fully
developed, is very difficult to cure. The use of a high
calcium concentration (7.5 mg/100 ml) in the dialysate
fluid can, in the long run, only arrest the progression
of the secondary hyperparathyroidism, which norm-
ally occurs using intermediate (6 to 6.4 mg/100 ml)
dialysate calcium concentrations. Prolonged treatment
with vitamin D3 can effectively suppress parathyroid
hormone hypersecretion, at least in selected patients,
but continuous treatment, with progressively lower
doses, is necessary to keep the parathyroid glands sup-
pressed. This is not unexpected since persistent hyper-
parathyroidism has been demonstrated [44] even more
than three years after restoration of normal vitamin D
metabolism [45] by successful renal transplantation,
thus indicating that involution of hyperplastic para-
thyroid glands is usually a very slow process. Of course,
whether this effective PTH suppression occurred by a
direct effect of vitamin D or by its influence on the
serum calcium concentration cannot be derived from
these studies in vivo.
Side-effects, especially metastatic calcification, have
previously been reported both during the use of high-
calcium dialysis [46] and vitamin D treatment [47].
However, with regular monitoring of the serum elec-
trolyte concentrations (with special attention to con-
tinuous normalization of the serum phosphorus con-
centration), we have been able to see even disappearance
of preexisting vascular calcification in patients on long-
term repetitive hemodialysis treated with pharmalo-
gic doses of vitamin D3 [48]. Nevertheless, the present
doses of vitamin D3 would probably be much too
high for patients without manifest renal osteo-
dystrophy.
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